Active, not recruitingPhase 1NCT02932956

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

Studying Combined hepatocellular carcinoma and cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Baylor College of Medicine
Principal Investigator
David Steffin, M.D., M.D
Baylor College of Medicine
Intervention
GAP T cells(genetic)
Enrollment
10 enrolled
Eligibility
1-21 years · All sexes
Timeline
20182037

Study locations (1)

Collaborators

Center for Cell and Gene Therapy, Baylor College of Medicine · Cancer Prevention Research Institute of Texas · The V Foundation · Cookies for Kids' Cancer · Curing Kids' Cancer Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02932956 on ClinicalTrials.gov

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma

← Back to all trials